- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-IL17F/ CANDF6/ IL-17F functional antibody
Anti-IL17F/ CANDF6/ IL-17F functional antibody for cell culture, ELISA & in-vivo assay
Go to IL17F/IL17F products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T06542-Ab-1/ GM-Tg-hg-T06542-Ab-2 | Anti-Human IL17F monoclonal antibody | Human |
| GM-Tg-rg-T06542-Ab-1/ GM-Tg-rg-T06542-Ab-2 | Anti-Rat IL17F monoclonal antibody | Rat |
| GM-Tg-mg-T06542-Ab-1/ GM-Tg-mg-T06542-Ab-2 | Anti-Mouse IL17F monoclonal antibody | Mouse |
| GM-Tg-cynog-T06542-Ab-1/ GM-Tg-cynog-T06542-Ab-2 | Anti-Cynomolgus/ Rhesus macaque IL17F monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T06542-Ab-1/ GM-Tg-felg-T06542-Ab-2 | Anti-Feline IL17F monoclonal antibody | Feline |
| GM-Tg-cang-T06542-Ab-1/ GM-Tg-cang-T06542-Ab-2 | Anti-Canine IL17F monoclonal antibody | Canine |
| GM-Tg-bovg-T06542-Ab-1/ GM-Tg-bovg-T06542-Ab-2 | Anti-Bovine IL17F monoclonal antibody | Bovine |
| GM-Tg-equg-T06542-Ab-1/ GM-Tg-equg-T06542-Ab-2 | Anti-Equine IL17F monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T06542-Ab-1/ GM-Tg-hg-T06542-Ab-2; GM-Tg-rg-T06542-Ab-1/ GM-Tg-rg-T06542-Ab-2; GM-Tg-mg-T06542-Ab-1/ GM-Tg-mg-T06542-Ab-2; GM-Tg-cynog-T06542-Ab-1/ GM-Tg-cynog-T06542-Ab-2; GM-Tg-felg-T06542-Ab-1/ GM-Tg-felg-T06542-Ab-2; GM-Tg-cang-T06542-Ab-1/ GM-Tg-cang-T06542-Ab-2; GM-Tg-bovg-T06542-Ab-1/ GM-Tg-bovg-T06542-Ab-2; GM-Tg-equg-T06542-Ab-1/ GM-Tg-equg-T06542-Ab-2 |
| Products Name | Anti-IL17F monoclonal antibody |
| Format | mab |
| Target Name | IL17F |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-IL17F benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-INN-996 | Pre-Made Sonelokimab Biosimilar, Bispecific, Anti-ALB;IL17A/IL17;IL17F Antibody: Anti-FDAHT/HSA/PRO0883/PRO0903/PRO1341;CTLA-8/CTLA8/IL-17A/ILA17;CANDF6/ML-1/ML1 therapeutic antibody |
| Target Antigen | GM-Tg-g-T06542-Ag-1 | Recombinant multi-species IL17F/ CANDF6/ IL-17F protein |
| Cytokine | GM-Tg-g-T06542-Ag-1 | Interleukin 17F (IL17F) protein |
| ORF Viral Vector | pGMLP002770 | human IL17F Lentivirus plasmid |
| ORF Viral Vector | vGMLP002770 | human IL17F Lentivirus particle |
| ORF Viral Vector | pGMLPm000115 | mouse 0 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm000115 | mouse 0 Lentivirus particle |
Target information
| Target ID | GM-T06542 |
| Target Name | IL17F |
| Gene ID | 112744,257630,301291,708220,481838,101095826,506030,100069094 |
| Gene Symbol and Synonyms | CANDF6,IL-17F,IL17A,IL17F,ML-1,ML1 |
| Uniprot Accession | Q96PD4,Q5BJ95 |
| Uniprot Entry Name | IL17F_HUMAN,IL17F_RAT |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | Therapeutics Target, INN Index, Cytokine Target |
| Disease | N/A |
| Gene Ensembl | ENSG00000112116 |
| Target Classification | N/A |
The target: IL17F, gene name: IL17F, also named as CANDF6, IL-17F, ML-1, ML1. The protein encoded by this gene is a cytokine that shares sequence similarity with IL17. This cytokine is expressed by activated T cells, and has been shown to stimulate the production of several other cytokines, including IL6, IL8, and CSF2/GM_CSF. This cytokine is also found to inhibit the angiogenesis of endothelial cells and induce endothelial cells to produce IL2, TGFB1/TGFB, and monocyte chemoattractant protein-1. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
